Bone Cancer Drugs Market, By Drug Type ( Antimetabolites, Anthracyclines, Antibiotics, and Others (RANK ligand inhibitors, etc.)), By Disease Indication (Multiple Myeloma, Osteosarcoma, Chondrosarcoma, and Ewing’s Sarcoma), By Distribution Channel, Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Sep 2023

Code : CMI93

Pages :204

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Global Bone Cancer Drugs Market: Key Developments

On August 10, 2023, Johnson & Johnson Private Limited, a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had granted accelerated approval for TALVEY (talquetamab-tgvs), a first-in-class bispecific antibody for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody

In November 2021, Pfizer Inc., a pharmaceutical company, announced the acquisition of Trillium Therapeutics Inc., a clinical stage oncology company, to develop innovative therapies for the treatment of cancer

In January 2021, FUJIFILM Holdings Corporation, a Japan-based multinational conglomerate, announced the launch of medical screening service business in India and other emerging countries in regions such as Southeast Asia, Middle East and Africa for the detection of various types of cancers such as bone cancer, lung cancer, breast cancer, cervical cancer, and others

In October 2020, Johnson & Johnson Private Limited, a global pharmaceutical company, announced that it had compelted the acquisition of Momenta Pharmaceuticals, Inc., a pharmaceutical company, to provide further upside potential for various diseases such as infectious diseases and vaccines, neuroscience, oncology, and pulmonary hypertension.